Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D001769:Blood; D001855:Bone Marrow Diseases / Q000150:complications*; D002675:Child, Preschool; D003110:Colonic Neoplasms / Q000150:complications; D057487:Enzyme Therapy; D005260:Female; D006801:Humans; D007938:Leukemia / Q000150:complications; D008223:Lymphoma / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000150:complications; D011087:Polycythemia Vera / Q000150:complications; D011743:Pyrimidines / Q000627:therapeutic use*; D012509:Sarcoma / Q000150:complications*; D014527:Uric Acid; D014545:Urinary Calculi / Q000517:prevention & control; D014969:Xanthine Oxidase
D000970:Antineoplastic Agents; D011743:Pyrimidines; D014527:Uric Acid; D014969:Xanthine Oxidase